{"organizations": ["ResMed Inc", "ResMed Inc.", "SAN DIEGO"], "uuid": "f175576b2c2870c4bbe407f99256c89c9356a461", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.bio-medicine.org", "main_image": "", "site_section": "http://www.bio-medicine.org/inc/biomed/medicine-technology.asp", "section_title": "Latest Medical Technology from Bio-Medicine.Org", "url": "http://www.bio-medicine.org/medicine-technology-1/ResMed-Inc--Announces-Results-for-the-First-Quarter-of-Fiscal-Year-2016-49238-1/", "country": "US", "title": "ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2016", "performance_score": 0, "site": "bio-medicine.org", "participants_count": 0, "title_full": "ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2016", "spam_score": 0.0, "site_type": "news", "published": "2015-10-22T12:37:00.000+03:00", "replies_count": 0, "uuid": "f175576b2c2870c4bbe407f99256c89c9356a461"}, "author": "", "url": "http://www.bio-medicine.org/medicine-technology-1/ResMed-Inc--Announces-Results-for-the-First-Quarter-of-Fiscal-Year-2016-49238-1/", "ord_in_thread": 0, "title": "ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2016", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "RSS Navigation Links HOME >> MEDICINE >> TECHNOLOGY ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2016 ...SAN DIEGO Oct. 22 2015 /- ResMed Inc. (NYSE: Analysis of first quarter results In the first quarter of fi... http://feeds.bio-medicine.org/latest-medical-technology Date:10/22/2015 \nSAN DIEGO,   -- ResMed Inc. (NYSE: RMD ) today announced results for its quarter ended September 30, 2015. Revenue for the quarter was $411.6 million, an 8 percent increase compared with the quarter ended September 30, 2014 (a 15 percent increase on a constant currency basis). \n\"Our global team was able to drive strong double-digit constant currency growth in the first quarter of fiscal year 2016. This result was led by 39 percent flow generator and 9 percent mask growth in the Americas,\" said Mick Farrell, ResMed's chief executive officer. \"We are investing for ongoing expansion and leadership in our high-growth regions. In October, we completed the acquisition of Curative Medical, making our combined ResMed and Curative business the market leader in sleep-disordered breathing and respiratory care in China.\" \nFarrell continued, \"It has been a year since we launched our Air Solutions Platform. We have made incredible progress, with over one million patients with cloud-connected devices on bedside tables, providing actionable data every day for patients, customers, providers and payors. Our leading informatics capabilities enable our global team to enhance and deliver the most innovative products and solutions that improve patient outcomes, create efficiencies for our customers, help providers better manage chronic disease and lower healthcare costs. We have established ourselves as leaders in the field of connected care and digital health.\" \nAnalysis of first quarter results In the first quarter of fiscal year 2016, revenue in the Americas was $254.2 million, a 23 percent increase over the prior year's quarter. Revenue in combined EMEA and APAC was $157.5 million, a 9 percent decrease compared with the quarter ended September 30, 2014 (a 5 percent increase on a constant currency basis). \nGross margin was 58.0 percent in the first quarter of fiscal year 2016, lower than the prior year's quarter mainly due to an unfavorable product mix, declines in average selling prices and an unfavorable geographic mix. \nIncome from operations for the quarter was $98.0 million, a 4 percent increase compared with the quarter ended September 30, 2014. Non-GAAP income from operations for the quarter was $100.3 million, a 4 percent increase compared with the quarter ended September 30, 2014. \nSelling, general and administrative expenses were $111.1 million for the first quarter of fiscal year 2016, a 1 percent increase (an 11 percent increase on a constant currency basis) over the quarter ended September 30, 2014. SG&A expenses improved to 27.0 percent of revenue in the quarter, compared with 29.1 percent in the quarter ended September 30, 2014. \nResearch and development expenses were $27.2 million for the first quarter of fiscal year 2016, or 6.6 percent of revenue. R&D expenses decreased by 9 percent (a 12 percent increase on a constant currency basis) compared with the quarter ended September 30, 2014. \nAmortization of acquired intangible assets was $2.3 million during the quarter. Stock-based compensation costs incurred during the quarter of $12.4 million consisted of expenses associated with employee equity grants, and the company's employee stock purchase plan. \nNet income for the quarter was $80.4 million, a 3 percent decrease compared with the quarter ended September 30, 2014. Non-GAAP net income for the quarter ended September 30, 2015 was $82.1 million, a 3 percent decrease compared with the quarter ended September 30, 2014 (non-GAAP measures exclude the impact of amortization of acquired intangibles). \nDiluted earnings per share for the quarter were $0.57. Non-GAAP diluted earnings per share for the quarter were $0.58. \nCash flow from operations for the quarter was $122.1 million. \nShare repurchase program During the quarter, the company repurchased 1.2 million shares at a cost of $62.0 million, as part of its ongoing capital management program. \nDividend program The ResMed board of directors today declared a quarterly dividend of $0.30 per share. The dividend will have a record date of November 19, 2015, payable on December 17, 2015. The dividend will be paid in U.S. currency to holders of ResMed's common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be November 17, 2015 for common stock holders and for CDI holders. ResMed has received a waiver from the ASX's settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from November 18, 2015 through November 19, 2015, inclusive. \nWebcast details ResMed will discuss its financial and business results and outlook on its webcast at 1:30 p.m. U.S. Pacific Standard Time today. The live webcast of the call can be accessed on ResMed's Investor Relations website at investors.resmed.com . Please go to this section of the website and click on the icon for the \"Q1 2016 earnings webcast\" to register and listen to the live webcast. The online archive of the broadcast will be available on ResMed's website after the live call. In addition, a telephone replay of the conference call will be available approximately two hours after the call by dialing 855-859-2056 (U.S.) and +1 404-537-3406 (international) and entering a passcode of 43449699. The telephone replay will be available until November 5, 2015. \nAbout ResMed The global team at ResMed (NYSE: RMD ) is united in the commitment to change millions of lives with every breath. With more than 4,000 employees and a presence in over 100 countries, the company has been pioneering new and innovative devices and treatments for sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic diseases for more than 25 years. ResMed's world-leading products and innovative solutions improve the quality of life for millions of patients worldwide, reduce the impact of chronic disease, and save healthcare costs. For more information about ResMed and its businesses, visit www.resmed.com or follow @resmed on Twitter. \nSafe harbor statement Statements contained in this release that are not historical facts are \"forward-looking\" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements—including statements regarding ResMed's projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products—are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed's periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements. \nInvestors:", "external_links": [], "published": "2015-10-22T12:37:00.000+03:00", "crawled": "2015-10-23T05:40:57.717+03:00", "highlightTitle": ""}